Cancer remains a leading cause of global mortality, with therapeutic challenges primarily arising from drug resistance and limited treatment efficacy. Polypharmacology—the strategic use of multi-target drugs or synergistic drug combinations—has emerged as a transformative approach to address these limitations. The journal Current Pharmaceutical Analysis is pleased to announce a special issue focusing on cutting-edge advancements in polypharmacology for cancer therapy, with an emphasis on mechanisms of drug resistance, rational design of drug combinations, and computational and AI-driven methodologies for discovering novel polypharmacological agents.
Topics Covered
We invite submissions of Full-Length Articles, Reviews, Editorials, Correspondence, and Short Communications on the following themes:
Multi-Target Drug Design
Discovery of compounds targeting multiple cancer-related pathways.
Structure-activity relationship (SAR) studies for polypharmacological agents.
Overcoming Drug Resistance
Inhibition of compensatory signaling pathways in resistant tumors.
Epigenetic and metabolic adaptations in resistance, and polypharmacological interventions.
Synergistic Drug Combinations
High-throughput screening for optimal drug synergies.
Nanotechnology-based delivery systems for combination therapies.
Computational and AI Approaches
Network pharmacology and machine learning models for drug interaction prediction.
Virtual screening of multi-target inhibitors.
Important Dates
Submission Deadline: July 10, 2026
Submission Instructions
Manuscript types accepted include Full Length Articles, Reviews, Editorials, Correspondence, and Short Communications.
An Article Processing Charge (APC) of $1680 will apply, with a 20% discount for this special issue.
You can contact us via email: editorial@fargroups.com
Guest Editors
Gary A. Piazza, Ph.D.
Affiliation: Auburn University, Department of Drug Discovery and Development, Harrison College of Pharmacy; Auburn, AL 36849, USA.
Research Interests: Signal transduction, cancer biology, phosphodiesterase, cyclic guanosine monophosphate, β-catenin, RAS
Zhe-Sheng (Jason) Chen
Affiliation: College of Pharmacy and Health Sciences, St. John’s University, New York, 11439, USA
Research Interests: Drug resistance and its reversal in cancer
Adam B. Keeton
Affiliation: Auburn University Harrison College of Pharmacy; Auburn, AL 36849, USA.
Research Interests: Oncology, Targeted Drug Discovery, Assay Development.
Angela I. Calderón
Affiliation: Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University
Research Interests: Botanical drug interactions, Integration of bioactivity to mass spectrometry of natural products using Computational and statistical tools, MS-based bioassays, and natural products chemistry.
Keywords
Polypharmacology, Cancer therapy, Drug resistance, Combination therapy, Multi-target drugs, Precision oncology
For more information, please contact the editorial office via email: editorial@fargroups.com